Becaris Publishing Limited

So much has happened in 2024 within real-world evidence (RWE), health technology assessment (HTA), and value-based care - it's certainly kept us busy at The Evidence Base®! But the big question remains: what’s next? In my latest article, I share insights from leading experts who explore the trends, challenges, and opportunities that will shape 2025. Many thanks to everyone who shared their thoughts with me: Stuart McCully, Dr. Rachele Hendricks-Sturrup, Kimberly Westrich, Blythe Adamson, PhD, MPH, Sreeram Ramagopalan, Nathan Buchbinder, Jonathan Pearson-Stuttard, Terry Myerson, Tim Disher, Ben Bray, Richard Chapman, Tara Cowling, Catrin Treharne and Jasim Uddin. Read the article at The Evidence Base® https://lnkd.in/e7NYfjqR #RealWorldEvidence #RWE #HTA #HealthTechnologyAssessment #ValueBasedCare #HealthcareInnovation

With The Evidence Base® being a media partner for ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024, I share my insights as a first-time attendee of the conference. Read at The Evidence Base® #ISPOREurope2024 #heor #healtheconomics #outcomesresearch #rwd #rwe #realworlddata #realworldevidence #AI #HTA #healthtechnologyassessment #healthdata #artificialintelligence

As the European Union's Health Technology Assessment Regulation (EU HTAR) prepares to take effect on January 12, 2025, stakeholders across the healthcare ecosystem are faced with a pivotal opportunity to reshape the evaluation and adoption of new medicines and health technologies. However, the path to achieving this is neither straightforward nor without challenges. During ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024, Herbert Altmann (Cencora) led an informative session exploring the topic, “Ready for 2025? How Lessons Learned From National System Reforms Can Guide Our Response to the New EU HTA Regulations.” Including panelists: Iga Lipska MD PhD MPH (Health Policy Institute Poland), Francois Meyer (FIPRA Public Affairs), Oriol Solà-Morales (Fundació HiTT), Mihai Iulian Rotaru (EFPIA - European Federation of Pharmaceutical Industries and Associations) and Max Brosa (formerly Managing Director, PharmaLex). Read the Deep Dive into the session at The Evidence Base® #heor #healtheconomics #outcomesresearch #healthoutcomes #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy #ISPOREurope #JCA #jointclinicalassessment #euhtar

Be sure to catch up on this Peek Behind the Poster interview with Alex Ide (BC Platforms). Alex discusses the research behind his recent poster at ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024, entitled “A Global Data and Secured Data Environment Technology Framework to Support Healthcare Decision-Making with Real-World Data”. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #healthoutcomes #rwe #rwd #realworldevidence #realworlddata #healthdata #ISPOREurope

On December 3, 2024, Canada House in London hosted “Real-World Evidence & Big Data in Healthcare: A Canada-UK Discussion,” an event co-organized by the High Commission of Canada in the United Kingdom | Haut–commissariat du Canada au Royaume–Uni and AxialBridge. Experts from academia, government, industry, and healthcare—including Axel Heitmueller, Tara Cowling, Harsimran Bajwa, Sigal Hachlili Dwyer, and Femida Gwadry-Sridhar—explored how #realworldevidence and #bigdata can drive innovation, enhance #patientoutcomes, and transform healthcare systems in Canada and the UK. Read at The Evidence Base® #rwe #realworlddata #rwd #healthdata

At the #2024ISPEAnnual Meeting, experts convened to discuss the theme, ‘Real-World Data-Based External Controls for Assessing Long-Term Benefit–Risk of Cell and Gene Therapies: Insights and Perspectives’. In this interview, we speak with the panelists; Hannah Furby, Reese S., Avery McIntosh, Carla Vossen, Erwan Muros-Le Rouzic, Reid D'Amico, Ph.D. and Seun Osundolire, to explore the opportunities and challenges of utilizing #RWD to assess the comparative long-term benefits of #CGTs. Read at The Evidence Base®: https://lnkd.in/epmBTDjT #realworlddata #realworldevidence #rwe #clinicaltrials #raredisease #orphandrugs #cellandgenetherapies

Reducing health disparities among different subpopulations is critical to achieving a fairer distribution of health outcomes, yet the challenge lies in quantifying and valuing equity improvements alongside traditional measures of efficiency. While #healtheconomics has advanced methodologies to measure total health benefits, incorporating equity into health technology evaluations is still in its early stages. By exploring concepts like distributional cost-effectiveness analysis and new approaches such as generalized cost-effectiveness analysis, Richard Willke (Principal, Scintegral Health Economics) delves into the evolving methods to measure, value, and prioritize #healthequity. Read at The Evidence Base® #heor #outcomesresearch #healthoutcomes #rwe #rwd #realworldevidence #realworlddata #marketaccess #medicalaffairs #hta #healthtechnologyassessment #healthdata #healthpolicy #valueassessment

Register for this upcoming #webinar from the PCSIG, hosted by The Evidence Base® Unlocking the future of blood collection: a step-by-step guide for the performance assessment of capillary sampling methods - Jan 15, 2025 As alternative #bloodsampling methods continue to grow due to #phlebotomist shortages and the need for person-centered care, it is vital to support these innovations with solid scientific validation. In this webinar, Vincent Molenaar (Leiden University Medical Center and Greiner Bio-One International) introduces the σ3-methodology, a #SixSigma-based approach developed to measure and verify the accuracy and precision of alternative blood sampling methods. Of specific interested for: - #Clinicallaboratory professionals seeking to improve sampling accuracy. - #Qualityassurance specialists in #diagnostic labs. - Researchers exploring alternative sampling methods. - #Regulatory affairs professionals in healthcare. - Healthcare providers interested in patient-friendly sampling options. Moderated by Neil Spooner (Founder, PCSIG) Made possible by the PCSIG sponsors: Altasciences, Alturas Analytics, Inc., Artyc, BENTO BIOLOGY PLATFORMS, Boehringer Ingelheim, Capitainer, Celerion, Charles River Laboratories, Genentech, GSK, MSD, Neoteryx, IQVIA Laboratories, Pfizer, RedDrop Dx, Resolian, Roche, Slope, Takeda, Tasso, Inc., Veloxity Labs, LLC and Waters Corporation. #patientcentricity #microsampling

BC Platforms, the University of Nottingham, and Nottingham University Hospitals NHS Trust are continuing their collaboration to enhance secure data sharing, research, and #healthcareoutcomes with tools including #trustedresearchenvironments. Read The Evidence Base® #rwd #realworlddata #healthdata #TREs

Register for this upcoming #webinar from The Evidence Base®, sponsored by Truveta. Harnessing real-time EHR data for post-approval studies Jan 21, 2025; 2pm ET, 11am PT, 7pm GMT, 8pm CET Post-approval safety studies can reveal risks that #clinicaltrials miss, especially for underrepresented populations like pregnant women, who are typically excluded from pre-market research. These studies are essential for understanding real-world drug and device effects, yet existing datasets are often fragmented, outdated, or cumbersome to analyze. This webinar will demonstrate how regulatory-grade #EHR data from over 120 million patients, including clinical notes and images, can overcome these challenges. Learn how real-time data is transforming safety studies and uncover new possibilities for advancing pregnancy safety research using detailed mother-child data. Speakers: Conor Wyand (Senior Director, Partner Solutions, Truveta) and Sarah Stewart, MD (Director of Clinical Informatics, Truveta). Register today! #heor #healtheconomics #outcomesresearch #healthoutcomes #rwe #rwd #realworldevidence #realworlddata #healthdata #healthequity #valueassessment